Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%

NARecruitingINTERVENTIONAL
Enrollment

270

Participants

Timeline

Start Date

July 30, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 29, 2028

Conditions
Prostate CancerProstate Adenoma
Interventions
PROCEDURE

RARP±SRT

Participants will undergo robot-assisted radical prostatectomy (RARP). Upon biochemical recurrence, they will receive salvage radiotherapy: 52.5-62.5 Gy in 20-25 fractions/2.5-3.0 Gy per fraction, per 2025 AUA/ASTRO/SUO guidelines.

PROCEDURE

RARP+ePLND

Participants will undergo robot-assisted radical prostatectomy (RARP) with extended pelvic lymph node dissection (ePLND), encompassing bilateral removal of obturator, external iliac, internal iliac, and common iliac lymph nodes. The dissection field extends laterally to the genitofemoral nerve, medially to the bladder wall, proximally to the ureter crossing the common iliac vessels, and distally to the deep circumflex iliac vein and femoral canal.

Trial Locations (1)

221000

RECRUITING

Ruijin hospital, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER

NCT07115992 - Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7% | Biotech Hunter | Biotech Hunter